Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | AKT1 | P31749 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.41 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.40 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | CTSS | P25774 | 3/20 | 0.39 |
| ▸ | CTSL | P07711 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2736205 | 0.87 | HDAC3 (0.45) | ATML3MBTL1ALDH1A1LMNAPOLB | |
| SCHEMBL12249316 | 0.85 | MEN1 (0.41) | ATML3MBTL1ALDH1A1LMNAPOLB | |
| SCHEMBL7659115 | 0.84 | ATM (0.45) | ATML3MBTL1AKT1ITGA4ITGB7 | |
| SCHEMBL7893852 | 0.84 | ATM (0.45) | ATML3MBTL1AKT1ITGA4ITGB7 | |
| SCHEMBL28397926 | 0.82 | ATM (0.43) | ATML3MBTL1ALDH1A1AKT1HDAC3 | |
| SCHEMBL17965949 | 0.81 | MEN1 (0.47) | L3MBTL1ALDH1A1LMNAPOLBHSD17B10 | |
| SCHEMBL17965951 | 0.81 | MEN1 (0.47) | L3MBTL1ALDH1A1LMNAPOLBHSD17B10 | |
| SCHEMBL9013326 | 0.81 | MEN1 (0.47) | L3MBTL1ALDH1A1LMNAPOLBHSD17B10 | |
| SCHEMBL23005035 | 0.81 | ATM (0.45) | ATML3MBTL1ALDH1A1LMNAPOLB | |
| SCHEMBL2736191 | 0.81 | ATM (0.47) | ATMALDH1A1LMNAHSD17B10AKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 133 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9891239-B2 | Modulators of pharmacokinetic properties of therapeutics | GILEAD SCIENCES, INC. (US) | 2018-02-13 | — | — | US | disclosed |
| EP-3150586-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | Gilead Sciences, Inc. (US) | 2017-04-05 | — | — | EP | disclosed |
| US-9575080-B2 | — | — | 2017-02-21 | — | — | US | disclosed |
| US-9575080-B2 | — | — | 2017-02-21 | — | — | US | disclosed |
| EP-3112355-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | GILEAD SCIENCES, INC. (US) | 2017-01-04 | — | — | EP | disclosed |
| US-20160303088-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | GILEAD SCIENCES, INC. | 2016-10-20 | — | — | US | disclosed |
| EP-2487165-B1 | Modulators of pharmacokinetic properties of therapeutics | GILEAD SCIENCES INC (US) | 2016-09-14 | — | — | EP | disclosed |
| EP-2487162-B1 | Modulators of pharmacokinetic properties of therapeutics | GILEAD SCIENCES INC (US) | 2016-08-17 | — | — | EP | disclosed |
| EP-2487163-B1 | Modulators of pharmacokinetic properties of therapeutics | GILEAD SCIENCES INC (US) | 2016-08-17 | — | — | EP | disclosed |
| EP-2487161-B1 | Modulators of pharmacokinetic properties of therapeutics | GILEAD SCIENCES INC (US) | 2016-08-10 | — | — | EP | disclosed |
| US-5648511-A | Method for making intermediates useful in the synthesis of retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 1997-07-15 | — | — | US | disclosed |
| WO-1997018205-A1 | SUBSTITUTED SULFONYLALKANOYLAMINO HYDROXYETHYLAMINO SULFONAMIDE RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1997-05-22 | — | — | WO | disclosed |
| WO-1997018190-A1 | N-PROTECTED/N-SUBSTITUTED-BETA-AMINO HYDROXY SULFONATES | G.D. SEARLE & CO. (US) | 1997-05-22 | — | — | WO | disclosed |
| WO-1996028464-A1 | BIS-AMINO ACID HYDROXYETHYLAMINO SULFONAMIDE RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1996-09-19 | — | — | WO | disclosed |
| WO-1996028418-A1 | SULFONYLALKANOYLAMINO HYDROXYETHYLAMINO SULFONAMIDE RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1996-09-19 | — | — | WO | disclosed |
| WO-1996028465-A1 | HETEROCYCLECARBONYL AMINO ACID HYDROXYETHYLAMINO SULFONAMIDE RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1996-09-19 | — | — | WO | disclosed |
| WO-1996028463-A1 | AMINO ACID HYDROXYETHYLAMINO SULFONAMIDE RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1996-09-19 | — | — | WO | disclosed |
| EP-0730570-A1 | METHOD FOR MAKING INTERMEDIATES USEFUL IN SYNTHESIS OF RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1996-09-11 | — | — | EP | disclosed |
| WO-1996022275-A1 | METHOD OF PREPARING RETROVIRAL PROTEASE INHIBITOR INTERMEDIATES | G.D. SEARLE & CO. (US) | 1996-07-25 | — | — | WO | disclosed |
| WO-1995014653-A1 | METHOD FOR MAKING INTERMEDIATES USEFUL IN SYNTHESIS OF RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1995-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160303088-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | SLC10A1, SLC10A2, ABCB11 | ATM 4242/4885L3MBTL1 4154/4885ALDH1A1 994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.